Table 2.
Pathology at Diagnosis
DCIS ductal carcinoma in situ, ER estrogen receptor, PR progesterone receptor
| Clinically detected (n = 22) | Screen-detected (n = 92) | P-value | Interval cancers (n = 11) | Screen-detected (n = 64) | P-value | |
|---|---|---|---|---|---|---|
| All Women | Regular Screeners | |||||
| Tumor histology | < .01 | 0.01 | ||||
| DCIS | 0 (0%) | 20 (22%) | 0 (0%) | 13 (20%) | ||
| Invasive ductal | 18 (82%) | 70 (76%) | 9 (82%) | 50 (78%) | ||
| Invasive lobular | 0 (0%) | 2 (2%) | 0 (0%) | 1 (2%) | ||
| Other | 4 (18%) | 0 (0) | 2 (18%) | 0 (0%) | ||
| Tumor size, median (range)* | 1.6 (0.1, 4.3) | 0.6 (0.1, 8) | < .01 | 1.4 (0.1, 3.5) | 0.7 (0.1, 2.6) | 0.03 |
| ER positive | 12 (55%) | 48 (52%) | 0.81 | 5 (46%) | 35 (55%) | 0.51 |
| PR positive | 8 (36%) | 34 (37%) | 0.47 | 4 (36%) | 23 (36%) | 0.75 |
| HER2 positive | 0 (0%) | 3 (3.3%)** | 1 | 0 (0%) | 3 (5%)† | 1 |
| Nuclear grade* | 0.31 | 0.32 | ||||
| Low | 0 (0%) | 1 (1%) | 0 (0%) | 0 (0%) | ||
| Intermediate | 1 (5%) | 18 (25%) | 0 (0%) | 13 (26%) | ||
| High | 12 (55%) | 48 (67%) | 5 (46%) | 36 (71%) | ||
| Unknown | 9 (41%) | 5 (7%) | 6 (55%) | 2 (4%) | ||
| Pathologic T stage | < .01 | < .01 | ||||
| Tis | 0 (0%) | 21 (23%) | 0 (0%) | 13 (20%) | ||
| T1 | 8 (36%) | 65 (71%) | 5 (46%) | 49 (77%) | ||
| T2 | 12 (55%) | 4 (4%) | 5 (46%) | 2 (3%) | ||
| T3 | 0 (0%) | 2 (2%) | 0 (0%) | 0 (0%) | ||
| T4 | 1 (5%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
| Tx | 1 (5%) | 0 (0%) | 1 (9%) | 0 (0%) | ||
| Node positive* | 9 (41%) | 10 (14%) | 0.01 | 5 (46%) | 6 (12%) | 0.02 |
| Lymphovascular invasion present | 8 (36%) | 12 (13%) | 0.01 | 4 (36%) | 9 (14%) | 0.07 |
*
Among invasive cancers only
**
21 screen-detected patients (23%) had unknown HER2 status
†
13 screen-detected regular screener patients (20%) had unknown HER2 status